Fagron N.V. Logo

Fagron N.V.

Supplies compounding ingredients and solutions for personalized medicine to healthcare professionals.

FAGR | BR

Overview

Corporate Details

ISIN(s):
BE0003874915
LEI:
549300TRKRUFK2RRG779
Country:
Belgium
Address:
Venecoweg 20A, 9810 Nazareth
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fagron N.V. is a global pharmaceutical company that specializes in pharmaceutical compounding to advance personalized medicine. The company focuses on optimizing and innovating customized pharmaceutical care for hospitals, pharmacies, clinics, and prescribers. Fagron develops and supplies a wide range of products, including pharmaceutical raw materials, active pharmaceutical ingredients (APIs), excipients, and innovative compounding vehicles such as Pentravan® (a transdermal base) and SyrSpend® (oral suspending vehicles). By providing these solutions, Fagron empowers healthcare professionals to prepare sterile and non-sterile medications tailored to the unique needs of individual patients, thereby widening the therapeutic scope of prescribers worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-06 07:00
M&A Activity
Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acqui…
English 590.7 KB
2025-10-06 07:00
M&A Activity
Fagron verkrijgt goedkeuring door de mededingingsautoriteit in Brazilië voor de…
Dutch 488.0 KB
2025-09-29 19:00
Share Issue/Capital Change
Press release increase share capital 29 September 2025.pdf
English 148.8 KB
2025-09-29 19:00
Share Issue/Capital Change
Persbericht verhoging kapitaal 29 september 2025.pdf
Dutch 124.3 KB
2025-09-25 07:00
M&A Activity
Fagron announces the acquisition of UCP in North America and FDA inspection upd…
English 166.2 KB
2025-09-25 07:00
M&A Activity
Fagron kondigt de overname van UCP in Noord-Amerika aan en een update over de F…
Dutch 172.5 KB
2025-07-31 08:22
Earnings Release
Fagron delivers strong performance with 11% topline growth and 12% increase in …
English 209.5 KB
2025-07-31 08:22
Earnings Release
Fagron delivers strong performance with 11% topline growth and 12% increase in …
English 987.2 KB
2025-07-31 08:21
Earnings Release
Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van …
Dutch 205.8 KB
2025-07-31 08:21
Earnings Release
Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van …
Dutch 993.4 KB
2025-07-31 07:00
Interim Report
Fagron - IFS 30-07-2025 EN.pdf
English 1.6 MB
2025-07-31 07:00
Interim Report
Fagron - IFS 30-07-2025 NL.pdf
Dutch 1.6 MB
2025-07-31 07:00
Earnings Release
Fagron - H1 2025 PR EN.pdf
English 987.2 KB
2025-07-31 07:00
Earnings Release
Fagron - H1 2025 PR NL.pdf
Dutch 993.4 KB
2025-07-31 07:00
Interim Report
Fagron - IFS 30-07-2025 EN.pdf
English 1.6 MB

Automate Your Workflow. Get a real-time feed of all Fagron N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Fagron N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-23 Pulido Andrew Executive member Sell 85,000 1,803,351.50 EUR
2025-05-22 Pulido Andrew Executive member Buy 85,000 1,617,550.00 EUR
2025-05-02 De Jong Cornelia Neeltje Board Sell 12,689 263,834.55 EUR
2025-04-30 De Jong Cornelia Neeltje Board Sell 229 4,660.15 EUR
2025-04-29 De Jong Cornelia Neeltje Board Sell 10,000 201,500.00 EUR
2025-03-28 J. Verlinden Other Buy 24,551 453,702.48 EUR
2025-03-28 J. Verlinden Other Sell 17,930 344,047.56 EUR
2025-03-27 Padilla Rafael Board Buy 78,469 1,450,107.12 EUR
2025-03-27 De Jong Cornelia Neeltje Board Buy 45,418 839,324.64 EUR
2025-02-21 Bakker Vera Executive member Buy 773 15,000.00 EUR

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.